Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: 5-aminolevulinic acid; ALA; ALA PDT; Aminolevulinic acid hydrochloride

Latest Information Update: 22 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata
  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Phase I/II Acne vulgaris
  • No development reported Basal cell cancer; Glioma

Most Recent Events

  • 17 May 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to initiates a phase III trial for Glioma (Diagnostic, Newley-diagnostic, Metastatic disease) in China (PO) (NCT06417281)
  • 06 Mar 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase II trial in Cervical intraepithelial neoplasia and Human papillomavirus infections in China (Topical) (NCT06439433)
  • 06 Dec 2021 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Acne Vulgaris in China (Topical, Powder) (NCT04044898)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top